fasudil has been researched along with Eye Disorders in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, KJ | 1 |
| Hsieh, CM | 1 |
| Nepali, K | 1 |
| Liou, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Postoperative Use of Dextenza (Dexamethasome Ophthalmic Insert) vs a Standard Regimen of Topical Fluorometholone After PRK[NCT05587231] | Phase 4 | 60 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fasudil and Eye Disorders
| Article | Year |
|---|---|
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.
Topics: Administration, Ophthalmic; Drug Delivery Systems; Drug Design; Eye Diseases; Genetic Therapy; Human | 2020 |